Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 24, 2026

Is Shopify (SHOP) Now Fairly Priced After Recent Share Price Pullback?

View original at finance.yahoo.com
Is Shopify (SHOP) Now Fairly Priced After Recent Share Price Pullback? Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Simply Wall St is trusted by over 7 million individual investors worldwide

    60% confidence

  • Shopify's 1-year stock return is +1.5%, 3-year return is +73.8%, and 5-year return is -17.1%

    60% confidence

  • At ~$103 per share, Shopify trades at roughly a 3.6% discount to its DCF intrinsic value, indicating it is approximately fairly valued

    60% confidence

  • Shopify receives a value score of 1 out of 6 on Simply Wall St's valuation checks

    60% confidence

  • Analyst estimates and Simply Wall St extrapolations project Shopify's FCF to reach $6.4 billion by 2030

    60% confidence

  • Shopify's latest twelve month Free Cash Flow is approximately $2.1 billion

    60% confidence

  • Shopify's DCF intrinsic value is approximately $106.79 per share using a 2-Stage Free Cash Flow to Equity model

    60% confidence

Data points we hold from this source

Shopify Inc. · cash2.1 USD
Shopify Inc. · stock price103 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Is Shopify (SHOP) Now Fairly Priced After Recent Share Price Pullback? — Source | Via News | ViaNews EU